Traumatic Brain Injuries - Ann Arbor Rehabilitation Centers, Inc

New To Our Site

The
Gathering Place

Support Groups

Massage Therapy

Potential Importance Of Altropane In Diagnosis Of ADHD Discussed In Boston Globe Magazine

BACK

Boston Life Sciences' (NASDAQ: BLSI) will review the clinical development
strategy for its Attention Deficit Hyperactivity Disorder (ADHD) diagnostic
and therapeutic technologies at the BIO 2000 CEO & Investor Conference in
NewYork on Wednesday, February 16th.

The Company's diagnostic radioimaging agent, Altropane(TM), and its
potential application as the first objective, biochemical test for Attention Deficit
Hyperactivity Disorder (ADHD) is discussed in the current February 6, 2000
issue of the Boston Globe Magazine. The Boston Globe article details the
growing concern among parents, educators and health professionals regarding
the accuracy of current purely psychosocial criteria used to diagnose ADHD,
particularly in children, and the related problem of the inappropriate use
of potentially addictive stimulant medication for this poorly-defined
condition.

The potential utility of Altropane as an ADHD diagnostic was also previously
featured in the November 22, 1999 issue of Business Week. The initial
clinical study results demonstrating that Altropane could detect a significantly abnormal elevation in the number of dopamine transporters (DATs) in the brains of subjects with longstanding ADHD were published in the December 17, 1999 issue of the prestigious British medical journal The Lancet.

The Company expects to initiate its Phase II clinical trial at the end of the
first quarter of 2000, and will be submitting a Fast Track application for
Altropane in the ADHD indication based on `unmet medical need', since there
is presently no objective biologic test for ADHD available.

It is currently estimated that approximately 1.5 million adults and 5 million
children are categorized as ADHD, and an additional 500,000 new cases are
identified annually. The Company believes that Altropane, if approved, has
the potential to become one of the largest selling radiopharmaceuticals ever
developed.

The Company will also provide an important update at the BIO 2000 Conference
of its program to develop therapies for both Parkinson's Disease and ADHD. BLSI is developing novel diagnostics for Parkinson's Disease and ADHD as
well as treatments for cancer, autoimmune diseases, and central nervous system
disorders. In addition to Altropane, BLSI's products in preclinical
development include: Troponin I, a naturally-occurring anti-angiogenesis
factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth
factors for the treatment of acute and chronic CNS disorders; fusion toxins
for the treatment of cancer and multiple sclerosis; and transcription
factors that may control the expression of molecules associated with autoimmune
disease and allergies.

Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as expected timing and results of clinical trials,discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, the market size for the Company's products and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties and actual results may vary materially from these statements. Factors that may affect future results include: regulatory decisions, results of scientific data from clinical
trials; delays in the regulatory or development processes; the ability toobtain intellectual property protection, the outcome of discussions with potential partners, the availability and adequacy of financial resources, market acceptance of the Company's products and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on
Form 10-K/A.

Web Site Links Disclaimer: At certain places in this site, links to other web sites can be accessed. Links to other Internet sites are provided as a convenience only. These sites contain information created, published, and maintained by organizations independent of AARC,Inc..
We do not endorse, approve, certify or control these web sites or the opinions, information, products or services contained therein, and do not guarantee the accuracy, completeness, efficacy or timeliness of information located therein, or at any link contained in a linked site. Internet locations change frequently, so many of the links provided on this web site may no longer access the external web sites listed herein.
No Medical Advice: The information posted here is not intended to be and should not be considered medical advice, as it is designed to support, not replace, the relationship that exists between a patient and his or her existing healthcare provider. It is not a substitute for the professional medical advice, diagnosis or treatment provided by your physician, other qualified health provider or any information included by the manufacturer with or on any product. Never disregard professional medical advice or delay in seeking it because of something you have read on or through the AARC web site. If you think you may have a medical emergency, call your doctor or 911 immediately.
YOU SHOULD ALWAYS CONSULT A PHYSICIAN OR OTHER HEALTHCARE PROVIDER OF YOUR OWN CHOICE AND CAREFULLY READ ALL PACKAGING AND OTHER INFORMATION PROVIDED BY THE MANUFACTURER OF ANY MEDICAL PRODUCTS OR DEVICES BEFORE USING THEM.